SM
IONS icon

SG3 Management’s Ionis Pharmaceuticals IONS Stock Holding History

SG3 Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,780
Closed -$557K – 602
2022
Q1 		$547K Buy
14,780
+6,280
+74% +$206K 0.02% 576
2021
Q4 		$259K Sell
8,500
-10,000
-54% -$315K 0.01% 767
2021
Q3 		$620K Sell
18,500
-53,800
-74% -$2.03M 0.02% 552
2021
Q2 		$2.88M Buy
72,300
+52,300
+262% +$2.05M 0.1% 227
2021
Q1 		$899K Buy
20,000
+7,500
+60% +$418K 0.02% 632
2020
Q4 		$707K Sell
12,500
-4,500
-26% -$224K 0.01% 643
2020
Q3 		$807K Buy
+17,000
New +$944K 0.03% 464
2017
Q4 		– Sell
-18,500
Closed -$938K – 156
2017
Q3 		$938K Buy
+18,500
New +$969K 0.22% 75

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SG3 Management's IONS Position: Q2 2022 in Review

SG3 Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2022, closing a stake of 14,780 shares — an estimated $557K sold.

SG3 Management first reported a position in IONS in Q3 2017 and held it in 8 quarters. The position peaked at $2.88M in Q2 2021. 349 funds tracked by Wall St. Rank hold IONS as of Q2 2022.

  • SG3 Management reported no remaining Ionis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 14,780 Ionis Pharmaceuticals shares in Q2 2022, an estimated $557K.
  • SG3 Management first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 8 quarters.
  • SG3 Management's Ionis Pharmaceuticals position peaked at $2.88M in Q2 2021.
  • 349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.